GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it has received a sub-award under a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD), of the National Institutes of Health (NIH), to develop a gene-based drug therapy to treat severe balance disorders. GenVec will receive up to $1,125,000 over five years to support pre-clinical research in collaboration with Dr. Hinrich Staecker, University of Kansas Medical Center, leading to the development of a drug candidate for clinical testing.
